Micafungin
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Micafungin: From Invasive Fungal Infections to Urinary Tract Infection (Candiduria)
One-Sentence Summary
Micafungin is an echinocandin antifungal established for the treatment of invasive candidiasis and aspergillosis. The TxGNN model predicts it may also be effective for Candida urinary tract infection (candiduria), a direction currently supported by 13 case reports/case series in the literature but no registered clinical trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in evidence pack (drug not marketed in Germany; no license data) |
| Predicted New Indication | Urinary Tract Infection (Candiduria) |
| TxGNN Prediction Score | 99.03% |
| Evidence Level | L3 (predominantly case reports/case series; one multi-institutional retrospective study; no RCTs) |
| Germany Market Status | 未上市 (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the evidence pack. Based on general pharmacological knowledge, micafungin belongs to the echinocandin class of antifungals, which act by inhibiting β-1,3-D-glucan synthase, a key enzyme in fungal cell wall synthesis. This mechanism gives echinocandins potent activity against Candida species, including fluconazole-resistant strains such as C. krusei and C. glabrata.
Micafungin's established use is for invasive candidiasis, esophageal candidiasis, and antifungal prophylaxis in high-risk patients (e.g., HSCT recipients). Candiduria and Candida UTIs are caused by the same pathogen class, so the mechanistic rationale for extending use to the urinary tract is coherent. Historically, echinocandins have been considered suboptimal for UTIs due to low urinary excretion; however, the literature summarized below suggests that in practice, urinary drug concentrations achieved with micafungin — particularly at higher doses — may still be sufficient to eradicate candiduria, especially in patients with azole-resistant or difficult-to-treat Candida species.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29109159 | 2018 | Retrospective cohort | Antimicrob Agents Chemother | Multi-institutional study characterizing candiduria management patterns, including antifungal overuse in asymptomatic cases, among hospitalized patients |
| 27587066 | 2016 | Case series | Int Urol Nephrol | Reviewed rates of candiduria elimination in micafungin-treated hospitalized patients |
| 27424599 | 2016 | Case series (6 cases) | Int J Antimicrob Agents | Urinary micafungin levels sufficient to treat UTIs from fluconazole-resistant and hepatically compromised patients; supports TDM-guided dosing |
| 26937340 | 2016 | Case series (5 cases) | Med Mycol Case Rep | All patients receiving parenteral micafungin ≥6 days had resolution of candiduria within 30 days |
| 35146837 | 2022 | Case series (pediatric) | Pediatr Int | Reported treatment success rates of micafungin for hospital-acquired Candida UTIs in critically ill PICU patients |
| 31111613 | 2019 | Case report | Transplant Infect Dis | Increased-dose micafungin successfully eradicated chronic C. krusei UTI in a liver/kidney transplant recipient |
| 38827222 | 2024 | Case report | Front Pediatr | Micafungin used to treat catheter-associated C. glabrata urinary infection in a premature neonate |
| 40765059 | 2025 | Case report | J Pharm Health Care Sci | C. glabrata pyelonephritis and bacteremia in an SGLT2 inhibitor patient successfully treated with micafungin |
| 33520520 | 2020 | Case report | Cureus | Candida auris UTI in a multi-comorbid nursing home patient, highlighting emerging multidrug-resistant pathogen relevance |
| 38681664 | 2024 | Case report | Med Mycol Case Rep | Unilateral renal fungus ball caused by C. glabrata, confirmed susceptible to micafungin, managed with antifungal therapy and endoscopic extraction |
Germany Market Information
Micafungin is not currently marketed in Germany, and no drug authorization records are available in the evidence pack.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for candiduria is currently limited to case reports, small case series, and one retrospective multi-institutional study — there are no registered clinical trials or RCTs. Combined with a blocking data gap on TFDA/label safety warnings and contraindications, and the drug's non-marketed status in Germany, the evidence base is not yet sufficient to move beyond exploratory monitoring.
To proceed, the following is needed:
- TFDA/German label safety warnings and contraindications (currently a blocking data gap)
- Confirmed mechanism of action data from DrugBank
- Prospective or comparative clinical data on micafungin dosing/urinary pharmacokinetics for candiduria, given historical concerns about low urinary excretion
- Regulatory pathway assessment given the drug is not currently marketed in Germany
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.